LadRx Issues 2024 Update to Shareholders
- None.
- None.
Insights
The FDA's acceptance of the New Drug Application for arimoclomol marks a significant milestone for LadRx Corporation, potentially catalyzing a series of financial transactions that could influence the company's cash flow and funding for ongoing projects. The immediate $1 million payment from XOMA Corporation enhances LadRx's liquidity, which is crucial for a biopharmaceutical company in the capital-intensive phase of drug development. Furthermore, the anticipated additional milestone payment upon the first commercial sale of arimoclomol, albeit netting $600,000 due to unspecified deductions, represents an additional influx of funds. The timing of these payments, contingent on regulatory approvals and market launch, introduces a degree of uncertainty that investors must consider when evaluating LadRx's financial trajectory.
From a broader financial perspective, the successful progression of LADR-7 through the manufacturing and toxicology phases, leading to an IND submission, could be a pivotal driver of long-term value creation. However, the inherent risks of clinical development suggest that investors should closely monitor the outcomes of the toxicology studies and subsequent FDA feedback. The company's ability to secure patent protection in multiple jurisdictions for its LADR-based molecules further underscores the strategic importance of intellectual property in sustaining competitive advantage and potential revenue streams.
The acceptance of arimoclomol's NDA by the FDA is a critical step forward in the drug's regulatory pathway, indicating that the application is sufficiently complete to permit a substantive review. The PDUFA date provides a regulatory timeline for approval, which is a key inflection point for the company's development efforts. The drug's progress towards potential commercialization is of particular interest, as it reflects the company's ability to transition from R&D to a market participant. The potential approval and market entry of arimoclomol will also have implications for the therapeutic landscape, especially if the drug demonstrates a differentiated profile in efficacy or safety.
Regarding LADR-7, the completion of GMP production and the initiation of GLP toxicology studies are foundational steps in the preclinical development process. These steps are prerequisites for IND filing, which is necessary before clinical trials can begin. The company's communication regarding the expected timeline for IND submission and potential first-patient dosing by the end of 2024 provides insight into their development strategy and operational targets. The mention of potential delays due to toxicology or regulatory hurdles underscores the uncertainties inherent in drug development, which can impact project timelines and investment considerations.
LadRx's success in securing patents for its auristatin-based and maytansinoid-based drugs across various jurisdictions is a significant achievement in protecting its intellectual property. Patents are a fundamental element in the biopharmaceutical industry, granting the holder exclusive rights to commercialize their inventions for a set period. The strategic importance of these patents cannot be overstated, as they can prevent competitors from entering the market with similar drugs, thereby potentially increasing the commercial viability and life cycle of LadRx's products. The patents also add to the company's asset portfolio, which could be factored into the company's valuation by investors.
The successful prosecution of patents and the existence of additional patents pending provide a layer of future security for the company's innovation pipeline. However, the actual value of these patents will ultimately depend on the commercial success of the drugs they protect, the company's ability to defend them against infringement and the legal robustness of the patent claims in each jurisdiction.
FDA Acceptance of Arimoclomol Triggers
***
January 9, 2024
Dear LadRx Shareholders,
It was a busy close to 2023 and has already been an exciting start to 2024. We are pleased to provide the following updates on the subjects of arimoclomol and LADR-7.
Arimoclomol
In 2023, LadRx entered into an agreement with XOMA Corporation (NASDAQ: XOMA) (“XOMA”) in which LadRx transferred the economic rights from arimoclomol to XOMA in exchange for an upfront payment and subsequent payments upon the achievement of certain milestones. The first of those milestones is the notification of the sponsor, Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra”), by the
Development of LADR-7
As previously communicated, LadRx is working diligently towards entering the first-in-human studies of LADR-7, which is a targeted, controlled release form of the highly potent tubulin inhibitor auristatin-E. The Company is pleased to report that the production of approximately 100 grams of LADR-7 under Good Manufacturing Practices (“GMP”) has progressed smoothly, has been completed and the GMP LADR-7 currently in hand is sufficient to carry out final toxicology studies, and to initiate Phase IA studies in humans.
The Company has also initiated the Good Laboratory Practices (“GLP”) toxicology program that is expected to form the foundation of the Investigational New Drug (“IND”) application for LADR-7 to the FDA. In the fourth quarter of 2023, the Company submitted a pre-IND to the FDA, outlining our proposed toxicology program. If the FDA agrees with our proposed toxicology program, management expects the toxicology studies to be completed and the IND for LADR-7 to be filed with the FDA by the end of the third quarter of 2024 or the beginning of the fourth quarter of 2024. Absent a clinical hold from the FDA, this timeline should allow the Company to be ready for first-patient dosing with LADR-7 by the end of 2024 (the period for the FDA review of an IND is 30 days). If the Company encounters difficulties with the toxicology program or fails to meet the FDA’s requirements for the IND, the first-patient dosing could be substantially delayed.
With the
In the second half of 2023, the Company made material progress on the patent protection of its LADR-based molecules. LadRx’s auristatin-based drugs were granted patents in
We look forward to continuing to build on our momentum at LadRx and a successful 2024.
Sincerely,
Stephen Snowdy, PhD
CEO of LadRx
***
Forward-Looking Statements
This press release may contain certain statements relating to future results which are forward-looking statements, including whether the company’s strategic review will be successful and whether the stock split will help the company be more successful in evaluating strategic alternatives. These statements are not historical facts, but instead represent only LadRx’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of LadRx’s control. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements; and other risks and uncertainties described in the most recent annual and quarterly reports filed by LadRx with the SEC, including disclosures under the heading “Risk Factors,” and current reports filed since the date of the LadRx’s most recent annual report. All forward-looking statements are based upon information available to LadRx on the date the statements are first published. LadRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
About LadRx
LadRx Corporation (OTCQB: LADX) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer. LadRx transferred the royalty and milestone rights associated with its previously developed drugs, arimoclomol and aldoxorubicin, to XOMA Corporation (NASDAQ: XOMA) in exchange for
View source version on businesswire.com: https://www.businesswire.com/news/home/20240109293094/en/
Longacre Square Partners
Greg Marose / Charlotte Kiaie
ladrx@longacresquare.com
Source: LadRx Corporation
FAQ
What triggered the $1 million payment to LadRx?
What are the anticipated milestones for LadRx in 2024?
What is the Prescription Drug User Fee Act (PDUFA) date for arimoclomol?
What is LADR-7 and what stage of development is it in?